The campaign against Hydroxychloroquine has taken on almost epic proportions as Big Pharma and the globalists have put the drug squarely in their sites. Just yesterday the FDA revoked its emergency use authorization for Hydroxychloroquine in the treatment of Covid19.
Many studies have shown that Hydroxy is either ineffective and even harmful to patients who are Covid19 positive. Many other studies published by scientists all over the world have found Hydroxychloroquine to be very effective in treating patients with Coronavirus, however. Especially when used in combination with the antibiotic Azithromycin and the vitamin Zinc.
So much so that The Association of American Surgeons & Physicians filed a lawsuit against the FDA, HHS, Biomedical Advanced Research and Development Authority (BARDA), two if its sub-agencies and several “lead officers” of government agencies last week for interfering with patients’ access to the drug.
A major study published in the scientific journal The Lancet last month also showed Hydroxychloroquine to not be effective in treating Covid19, but that study was retracted soon after, when it was shown the data on which the study was based was false.
Today the FDA fired the latest blow in the battle against honest scientific data when they warned against combining Hydroxychloroquine with Gilead Sciences’ yet unproven Covid19 wonderdrug Remedesivir.
Promising results of Remdesivir in trials were announced several weeks ago. But upon further inspection, it seems Remdesivir did only a so-so job in treating Covid19 patients. That may explain why many Gilead executives decided to cash in on company stock soon after the “promising” results were announced. Perhaps they figured the news was never going to be as good for the drug as it was that day?
Still, even if it’s not proven to be a cure-all for Covid19, Gilead still manages to make a pretty penny from Remdesivir being added to the national stockpile, to the tune of $7 billion.
That may be the reason warnings are being issued now to keep Hydroxychloroquine from encroaching on any of Gilead’s potential market share.